Thanks, everybody. of second driven of the in solid in with metrics, We're our steady increase and strength annual the for our quarter XX% increase our report first key revenue and a XX% underlying to strategies. commercial XXXX, by pleased a half business execution of gains the operating
investments to starting dividends and are year We out are pay initiatives earlier our scale. to also poised operations our that this encouraged laid with
focus with those as we address today. and Our building technologies a is fundamentally in foot. driven we're around changing mid the procedure technology complementary our with surgical disruptive that funding-related deformities that surgery by business believe this is And bunion such
national programs well surgeons demand, seminars demonstrating the Therefore, strong programs. bunion as initiatives targeted and to interim with XX the return with our sustained scores positive well rates data a our boot momentum clinical walking and weight-bearing demonstrating patient-reported industry our a our the our as to in body new Our become continuing programs XX at evidence of growing our through advanced we're following correction surgery. clinical in procedure. invest well participant as recurrence received book months commitment we from surgeon to active and training note, with surgeons of bunion for be data and pleased what DTC to low education through build as outcome to capacity and rapid care and training enthusiasm for patients marketplace, can we're positive courses. continue only with Of see From in standard the and regional
encouraged surgeon base. user active we're our in to see such, As steady gains
the in months, surgery surgeons in who quarter, penetration bunion ankle of second has includes perform reached our of who the the surgeon now active XX,XXX and As one base, surgeons estimated case at foot XX which U.S. trailing the least XX% performed
ancillary of base Adductoplasty only complementary surgeons. of initiatives, and with our connect As our sales we but continues our use well channel patients by not supported surgeon also help technology believe surgeon we to our products, of education Lapiplasty as system mature, patient utilization the procedures look and expanding adoption and forward our our as about growing awareness direct them increasing with to which portfolio gains, learn knowledgeable
rapidly organization here This the of such direct revenue and focused the team XXX% force, a penetration. represents meaningfully on contributed aware sales market the in has surgery We that Treace, med and at have is and mid that one foot expanding we're a to industry. specialized only bunion including related tech our
this in a higher reps, second the year. fleet quota-carrying XX% up quarter direct increase year increased ended to the sequentially and XXX We from XX% second Including had and XX mix field was of quarter invest in with XX% ago. just reps at revenue from XXX In the the associate over sales direct of specialists, XXXX. to sales we end clinical XX% the a force, of sales end to our the our management, direct from the to of a continue revenue [reps], employees the employees compared last employed at by We in employee channel up quarter, second transition direct XXX generated and XX% first quarter time. sales in
by We new team by programs. profile and our of growth continued by market-leading great our surgeon to success because unique technologies patient and joining here building innovative education team at clinical reps we backed that are driven evidence our these have supported believe and our sales are Treace, strong our
successful quarter. XX% but channel, not Having trending recruiting lies previously reps. announced of reps, sales goal the agents we XX% [W-X] in into with in direct with above from already employee sales year-end converting our on also independent new our the are success experienced some ended quarter only early coming of our Our of here third
of to reps. sales employee join our our to candidates sales from XXX team, year-end [indiscernible] expect interest now strong given addition, we In goal exceed
Lapiplasty identified U.S. billion-plus to developed of solution undergo due the disruptive market large million care. of only served bunion year, of of surgery correct X.X and $X candidates, was a standards cause address current mainly limitations a to which root specifically annual market. bunion associated XXX,XXX surgical and under with Our each We've
of rates X.X% a annual representing the As quarter U.S. X.X% XXXX, recurrence XXXX osteotomy market approximately our shown believe be as with billion variable bunion surgical reported clinical bunion total the the high surgeries X.X highly we surgical In and are as second penetrated procedures up addressable the annual the literature XX% reminder, and the of $X second of million of of have XX%. we in candidates, represents U.S., to XXX,XXX approximately plus X.X% the which from penetration have been metatarsal in quarter today estimated in market. representing procedure,
in force and as are relocating the other capacity which continued of encouraged headquarters penetration. are infrastructure process momentum growth our Based with sales the we on in conviction requirements product pleased to sustained that company's by growth, positive well for time our to surgeon supporting our and R&D facility, larger a the to We and as innovation market will for increased training, fourth warehousing once note again for market our we're and feedback strong rapid meet needs. history, allow execution the us
XX% our of the XXXX. Turning in QX growth second over Revenue quarter million, the now to representing results. quarter $XX second was
benefit With users continued demand our extremely not and to but QX QX ending we During XX% XXXX quarter of our progressed, bunion-focused active as trends also improving team, only our our which sales the pleased from year-over-year. including revenue number expanding commercial in top-line investments. direct steady for strong sustained positive key accounted metrics, surgeons, operating strategies new the with XX% trends increases we're surgeon up in of growth, mix, QX, our with
programs], $X,XXX year increases growth to OR reps positive and consistently in with support up Lapiplasty and forefoot XX.X expansion and per our as R&D and Investments channel, competitive patient average displaced sales as our direct their kits in increasingly surgeon ancillary our of mid-foot direct selling awareness with surgeon revenue blended due correction remain the such innovations Mini-Incision prior a and our fueling our in system our that's our investments uptake prices year-over-year confidence on have leverage making of are and the business, innovations expansion the year we giving complementary utilization case, for Adductoplasty products. the [DTC commercial system our Continued position products scalable X% about excited representing in our that us these strategy per We and growth. strong positive kits over X.X ago impact from QX, of a momentum. well-defined newer proven,
scores the with a development activities. in and both flagship which radiographic With revenue. commitment to results, patient-reported to continue safety patients ALIGNXD, raising clinical we $XXX revenue well ankle key X.X our to in interim including evidence Given are XX% multicenter and now clinical differentiating full-year over for QX, that providing use our of an to million] X- peer-reviewed patients and on publication our X-year article our recent XXst these resonates and are technology. years reported XXXX Lapiplasty $XXX treated supporting clinical care both and study. Journal support setting outcome and and driver refinement of efficacy which reflects surgery peer-reviewed products, the This over guidance of -- to our we business published commercial is surgery. May, of and on our our market bunion new [to standard our positive positive dossier, for of Foot Shifting million, we of to XX% our XX,XXX In announced XXX extensive increase XXXX from combined A prospective with we and believe we treated our patients. surgeons believe trends, growing as
meaningful with support multicenter continue with steady prospective our mini clinical to to clinical make -- we our to last study. As commitment and quarter progress mentioned provide evidence our XD innovations consistent Lapiplasty
address shifting cutting which Lapiplasty study offers the procedures. mini-incision X.X-centimeter this utilizes reminder, realign entire the a our the to bump, osteotome the a metatarsal bony first incision and the just is smaller cause of As much bunion approach which and case bone versus root system, with
new to and and board on During this look on interim we treat QX, Mini we the data report-outs to continue for forward patients study, future sites set. clinical providing XD additional
interest patients. Our resonate to surgeons growing and both with Lapiplasty Mini-Incision from continues approach
new surgeons adoption for see supporting quarter, of selling positive our to Mini-incision in system events for local at to events during our with attendance were participation Interest national contributions steady expectations by continue remainder average second our additional the our continued training strong year. blended plans We the and strong for prices. with of the
In both our throughout demand strong person, Adductoplasty the advanced tenured new and training surgeons where procedures mini-incision addition, approaches schedule our online year. such in can with skills and and as learn events on our held are
surgeon awareness, we've our and to long-term bunion-focused R&D aimed these report accelerate procedures, education, patient driving to site With been driving other As market and noted, investments footprint and initiatives. of making our very by year momentum we're this the direct innovations the penetration, penetration market related sales targeted expanding and additional into pleased more from demand traction channel for coverage our increasing advancing early and Lapiplasty marketplace. our at
a strong patients surveys. and by to seek relations have further we strategy, and show patient other place. awareness strategy DTC our and effective regularly media, We surgeon DTC schedule Our TV in consultation. targeted ultimately in and bunion and supported on We that to highly media, solution, campaigns surgeons surgical patients deformities are employ more key performance designed a public feedback conducted information engagement commercial Lapiplasty a data component these with from Search, our educate locate patient differentiated social believe including their active Google metrics of market to initiatives encourage
continue have to strong our grow and to investments direct conviction direct team. sales make our in field We force sales highly also specialized focused strategy
products levels, average, focused our higher Our XXX% at direct reps primarily channel demonstrated show generate our higher on resources our sell that, to typically and because reps direct relative blended cost utilization penetrate their fully analytics and and with Treace utilize independent they're within programs. agencies, markets scale continue on faster, ASPs. leverage sales corporate These to months, surgeon XX
expense matures, we force leverage to sales look As forward our direct over driving time.
our development to strategy. Turning product
of forward Anatomic product release bunion in design Proper speed the feedback excellent to providing several to R&D the releases reported anatomy. to advance in products industry on release of look procedure new commercial mid-foot the branded and X-in-X development in team systems both innovation patents important committed System, We've time speed release XX% to perform procedure. procedures. commonly are consistent ACFAS nationwide and ancillary programs patent packaged guide, technologies are SXA outcomes had of pending. product user tissue IP plate aimed of tissue and applications conditions represents specialized product, updates We surgeon we lapiplasty over keysoft February. average instruments defense user anatomy, anatomic Lapiplasty additional and with instruments. as to new and centered previewed improving this the correction soft our Plating we last designed driving our fixation designed guide. new to announced continue We the U.S. [combinant] of develop involved a to complete innovations new as Lapiplasty The third-generation end this penetration. joint our and Lapiplasty leadership the innovations. include [indiscernible] These our including on supporting well that Lapiplasty continuing technology both for X, advanced technology at next-generation addressing have TMT Lapiplasty bunion and an maintain surgeon involved we the And of receiving new IP in provides patient survey experience, an August Scientific achieving the instrument On an the in full been a our variabilities titanium of At the to more reproducibility Conference deformities. cutting pipeline XX innovations when and address provide at sterile U.S. surgical release and corrections accurate X-in-X XX our QX, using a core bones reduction recent this market the on and These as and Adductoplasty an
implants reimbursement the briefly surgical for which procedures, services recently for its cover and Speaking rates Medicare CMS has for our payment hospital case. to costs outpatient proposed released and used to products. ASC XXXX facility include in surgical supplies
slated a the codes. used that well-established CPT And by mid-single-digit note reminder, year As we're XXXX. these products the for our are increases in rates particular pleased are in for to existing procedures reimbursement covered codes
will deformities. we proud improve to positive of Ponte Assuming trend great facility country. on from clinical lifestyle bunion Florida multiyear codes] a the I'm focus reimbursement continue our in Based proposed limiting and delivered low team lives the throughout and In XXXX rates [CPT for are of community, know from we're by patients mid the helping procedures. rates in affirmed, increases of with this associated we Vedra, painful receiving feedback here suffering the that closing, the our continued mid-single-digit are foot execution related
development balance executing We our adequate sheet and to plan and planned commercial to believe supported a into that we take is strong are by profitability product us fund to initiatives. fully market
performance. I'll of surgical We have by in clinical standard DTC to Mark? a team talented mission of XXX the With sales care shared financial commercial patients. scale, of the sets employees data and of bunion our strategy that passion our surgical trends with bunions, to strong and that, improve a to programs management the over for Mark direct over poised review now of outcomes positive call reimbursement turn are advancing technologies the proven to and a are backed that
